梅花生物
(600873)
| 流通市值：318.84亿 | | | 总市值：318.84亿 |
| 流通股本：28.04亿 | | | 总股本：28.04亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 18,215,447,345 | 12,280,450,603.53 | 6,268,563,075.46 | 25,069,288,294.62 |
| 营业收入 | 18,215,447,345 | 12,280,450,603.53 | 6,268,563,075.46 | 25,069,288,294.62 |
| 二、营业总成本 | 15,834,727,996.42 | 10,368,912,543.02 | 5,214,885,039.05 | 21,862,599,657.62 |
| 营业成本 | 14,342,185,989.36 | 9,433,353,240.09 | 4,726,419,461.59 | 20,036,698,814.74 |
| 税金及附加 | 188,004,044.32 | 119,066,571.04 | 65,258,134.17 | 235,462,799.84 |
| 销售费用 | 273,352,514.87 | 167,760,792.02 | 86,222,231.72 | 386,866,509.47 |
| 管理费用 | 749,123,230.1 | 469,433,561.57 | 254,781,461.27 | 937,932,200.19 |
| 研发费用 | 296,016,607.21 | 199,958,697.93 | 103,233,375.21 | 382,903,265.05 |
| 财务费用 | -13,954,389.44 | -20,660,319.63 | -21,029,624.91 | -117,263,931.67 |
| 其中:利息费用 | 40,273,509.95 | 27,955,159.53 | 13,474,653.29 | 80,472,368.46 |
| 其中:利息收入 | 42,750,808.43 | 26,389,977.12 | 16,044,112.56 | 97,971,379.97 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 25,374,357.22 | 16,016,844.67 | 9,346,362.95 | 14,826,169.53 |
| 加:投资收益 | 42,049,338.03 | 29,250,766.79 | 13,629,411.31 | 30,193,009.09 |
| 资产处置收益 | 589,156.66 | 438,552.05 | 138,287.86 | 29,968.32 |
| 资产减值损失(新) | -9,348,180.66 | -9,236,606.64 | -180,993.48 | -6,981,927.26 |
| 信用减值损失(新) | 136,864.37 | -154,305.79 | - | 3,888,525.41 |
| 其他收益 | 219,409,461.61 | 148,546,316.33 | 129,419,775.43 | 242,640,414.38 |
| 四、营业利润 | 2,658,930,345.81 | 2,096,399,627.92 | 1,206,030,880.48 | 3,491,284,796.47 |
| 加:营业外收入 | 786,644,604.51 | 3,157,136.41 | 1,145,087.37 | 140,787,996.42 |
| 减:营业外支出 | 3,070,420.99 | 10,385,914.08 | 4,913,258.02 | 282,612,101.76 |
| 五、利润总额 | 3,442,504,529.33 | 2,089,170,850.25 | 1,202,262,709.83 | 3,349,460,691.13 |
| 减:所得税费用 | 417,412,174.28 | 321,220,733.36 | 183,556,343.37 | 609,033,475.57 |
| 六、净利润 | 3,025,092,355.05 | 1,767,950,116.89 | 1,018,706,366.46 | 2,740,427,215.56 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 3,025,092,355.05 | 1,767,950,116.89 | 1,018,706,366.46 | 2,740,427,215.56 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 3,025,092,355.05 | 1,767,950,116.89 | 1,018,706,366.46 | 2,740,427,215.56 |
| 扣除非经常损益后的净利润 | 2,019,475,140.77 | 1,628,363,104.4 | 904,569,095.36 | 2,696,673,816.43 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.06 | 0.62 | 0.36 | 0.94 |
| (二)稀释每股收益 | 1.06 | 0.62 | 0.36 | 0.94 |
| 八、其他综合收益 | -80,102,163.16 | -98,666,362.69 | -78,900,353.95 | -60,692,608.96 |
| 归属于母公司股东的其他综合收益 | -80,102,163.16 | -98,666,362.69 | -78,900,353.95 | -60,692,608.96 |
| 九、综合收益总额 | 2,944,990,191.89 | 1,669,283,754.2 | 939,806,012.51 | 2,679,734,606.6 |
| 归属于母公司股东的综合收益总额 | 2,944,990,191.89 | 1,669,283,754.2 | 939,806,012.51 | 2,679,734,606.6 |
| 公告日期 | 2025-10-30 | 2025-08-20 | 2025-04-22 | 2025-03-18 |
| 审计意见(境内) | | | | 标准无保留意见 |